BACK

Annabelle Guillermo

Annabelle Guillermo

Vice President

London Office  |  annabelle.guillermo@torreya.com   |   +44 (0) 207 451 4555

Annabelle Guillermo, a Vice President at Torreya, oversees transaction support work on a variety of European investment banking assignments.

She joined Torreya in 2011 from Bank of America Merrill Lynch, where she worked as a Healthcare Investment Banking Analyst.

Annabelle holds a B.Sc. in economics from University College London and attended Ateneo de Manila University in the Philippines. She is fluent in both English and Filipino.

Selected Transactions

Atopix
Company sale to
Chiesi
> €75 million
November 2016
DBV Technologies
License of
milk allergy product to
Nestle
€100 million
May 2016
Midatech Pharma
Acquisition of
Dara Biosciences
Up to $30 million
December 2015
Ipsen
Acquisition of
OctreoPharm Sciences
Up to €50 million
May 2015
SpePharm
Collaboration with
Norgine
Undisclosed
December 2012
Sandoz
Sale of selected
generic brands to
Samara Capital
Undisclosed
June 2017
arGEN-X
License of preclinical
derm antibody to
LEO Pharma
Up to €105 million
May 2015
Aseptix Health Sciences
License of antimicrobial technology to
Ecolab
Undisclosed
December 2014
Probiodrug
Financial advisor
on IPO
Undisclosed
$30 million
October 2014
DBV Technologies
Global offering advisory
Undisclosed
$133 million
October 2014
4-Antibody AG
Sale to
Agenus
$40+ million with
$10 million upfront
January 2014
DBV Technologies
Financial advisor in
private placement
Undisclosed
€29.9 million
November 2013
Inviragen
Sale of
vaccine company to
Takeda
$250 million with
$35 million upfront
May 2013
Selexis
Sale of basket of
royalties to
Ligand
$6 million upfront
April 2013